期刊文献+

自然杀伤细胞在头颈部鳞癌发展及治疗中的研究进展 被引量:3

Natural killer cell in the development and treatment of head and neck squamous cell carcinoma
下载PDF
导出
摘要 头颈部鳞癌是世界上最常见的恶性肿瘤之一,其转移率高,预后差,常给患者带来严重的面部损伤,以及进食、发音等功能障碍。自然杀伤细胞是先天免疫系统的效应细胞,具有直接识别并杀死肿瘤细胞的功能。自然杀伤细胞活化水平与头颈部鳞癌的预后密切相关,头颈部鳞癌的发生发展常伴随自然杀伤细胞的数量减少或功能被抑制。重新激活自然杀伤细胞可提高头颈部鳞癌的疗效。本文就自然杀伤细胞在头颈部鳞癌发展及治疗中的应用进行综述。 Head and neck squamous cell carcinoma(HNSCC)is one of the most common malignant tumors in the world.It has a high metastasis rate and a poor prognosis.HNSCC often brings severe facial deformitiesand dysfunctions such as eating and pronunciation to patients.Nature Killer cells(NK cells)are innate immune system effector cells that directly recognize and kill tumor cells.Studies have shown that NK cells activity are associated with the prognosis of HNSCC,and HNSCC developed with the reduction or inhibition of NK cells.Previous studies believe that natural killer cells can be reactivated to improve the curative effect of HNSCC,showing the potential of natural killer cells.This article reviews the application of natural killer cells in the development and treatment of HNSCC.
作者 王鹿鸣 谢尚 Lu-Ming WANG;Shang XIE(Peking University School of Stomatology,Beijing 100081,China;Department of Oral and Maxillofacial Surgery,Peking University Hospital of Stomatology,Beijing 100081,China;National Clinical Research Center for Oral Diseases,Beijing 100081,China;National Engineering Laboratory for Digital and Material Technology of Stomatology,Beijing 100081,China;Beijing Key Laboratory of Digital Stomatology,Beijing 100081,China)
出处 《医学新知》 CAS 2021年第1期33-41,共9页 New Medicine
基金 国家自然科学基金(82002878) 北京大学口腔医院青年基金项目(YS020219)。
关键词 自然杀伤细胞 头颈部鳞癌 免疫治疗 Nature killer cells Head and neck squamous cell carcinoma Immunotherapy
  • 相关文献

参考文献2

二级参考文献95

  • 1Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK ceil recognition. Immunol Today 1990, 11: 237-244.
  • 2Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol2008, 9: 503-510.
  • 3Orentas R J, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Bio12006, 16: 137-149.
  • 4Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immuno12003, 3: 253-257.
  • 5Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler R l. Galectin-l: a key effector of regulation mediated by CD4+CD25 T cells. Blood2007, 109: 2058-2065.
  • 6Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A. CD25 CD4 T cells regulate the expansion of peripheral CD4 T cells through the production of IL-IO. J Immunol 2001, 166: 3008-3018.
  • 7Col lison LW, Workman C J, Kuo TT, Boyd K, Wang Y, Vignali KM et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007: 450: 566-569.
  • 8Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti Jet al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immuno12010, 11:1093-1101.
  • 9Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4CD25+Foxp3 regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immuno12007, 8: 1353-1362.
  • 10Grossman W J, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity2004, 21: 589-601.

共引文献11

同被引文献22

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部